Pergamon

Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 11, pp. 1399-1402, 1997

0960-894X/97 $17.00 + 0.00

PII: S0960-894X(97)00228-X

N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide; One of a Class of Novel Benzenesulphonamides which are Orally-Active, ET_A-Selective Endothelin Antagonists

Andrew A. Mortlock* , Colin Bath, Roger J. Butlin, Christine Heys, Sarah J. Hunt, Alan C. Reid, Neil F. Sumner, Eric K. Tang, Elaine Whiting, Campbell Wilson and Nicola D. Wright.

ZENECA Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.

Abstract: A series of novel sulphonamides have been discovered which show high affinity and selectivity for the endothelin ET_A receptor. N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide (**18**) is the most widely investigated compound and is a potent antagonist *in vivo* when dosed either i.v. or orally, and has prolonged oral duration of action. © 1997 Elsevier Science Ltd.

Endothelin-1 (ET-1),[1] and the closely-related isopeptides endothelin-2 (ET-2) and endothelin-3 (ET-3) have been implicated in a number of disease states[2] such as renal failure,[3] cerebral vasospasm[4] and pulmonary hypertension.[5] In mammalian tissues, two subtypes of endothelin receptor have been identified.[6] The ET_A receptor binds ET-1 and ET-2 with greater affinity than ET-3 and is found mainly in vascular smooth muscle, where it mediates vasoconstriction[7] and smooth muscle proliferation.[8] The ET_B receptor binds ET-1, ET-2 and ET-3 with similar affinity and mediates primarily vasodilation but also vasoconstriction in certain vascular beds.[9]

Recently, the first non-peptide endothelin antagonists have been reported including a number of sulphonamides. These sulphonamides may be either ET_A-selective, such as BMS 182874,[10] or may be 'balanced' ET_A/ET_B antagonists, such as Ro 46-2005[11] and Ro 47-0203 (Bosentan).[12]



BMS182874



1 : R = Cl
2 : R = Br
3 : R = CH_3

We have recently described a series of ET_A-selective compounds (including **1-3**), discovered whilst preparing N-(5-(dimethylamino)-1-naphthalenesulphonamides using robotic synthesis.[13] Activity has also been reported in related sulphonamides, in which the dansyl moiety has been replaced by either 2-biphenyl or 2-(4-isobutylphenyl)phenyl group.[14] The work reported here concerns the introduction of carboxamide groups into the 3 position of N-(pyrazinyl)-2-arylbenzenesulphonamides. This work was undertaken in the hope that the newly introduced amide group might occupy the same region of space as was filled by the dialkylamino group in

* Fax: +44 1625 513910 E-mail: Andrew.Mortlock@Alderley.Zeneca.Com

compounds **1-3**, thereby possibly providing compounds with enhanced affinity and / or selectivity for the ET_A receptor over the activity seen with compounds **1-3** or **16/17**. The general route used to prepare such compounds is illustrated for the preparation of compound **8**, as shown in scheme 1, starting from 2-bromo-3-nitrobenzoic acid (**4**):-



Scheme 1

The compounds listed in Table 1 were evaluated in a radioligand binding assay involving displacement of [^{125}I]ET-1 from membranes prepared from MEL cells transfected with cloned human ET_A receptors.[15] A similar assay was used to measure affinity for the human ET_B receptor but the data are not shown as no compound showed significant binding (>50% inhibition at 10μM).[6] Data for the analogous biphenylsulphonamides, lacking the C3 carboxamide substituent (compounds 16 and 17) are also shown.

Table 1 - In vitro ET_A Binding Data for compounds 8-17

Compound	R_1	R_2	R_3	ET_A pIC_{50}
8	$-CH_3$	H	*i*-Bu	8.9
9	H	H	*i*-Bu	9.1
10	$-CH_2CH_2OCH_3$	H	*i*-Bu	8.8
11	-*n*-C_5H_{11}	H	*i*-Bu	6.7
12	$-CH_3$	$-CH_3$	*i*-Bu	9.0
13	H	H	H	7.4
14	$-CH_3$	H	H	7.4
15	-*n*-C_5H_{11}	H	H	8.4
16	-	-	*i*-Bu	7.4
17	-	-	H	7.5

For those compounds where R_3 is isobutyl, introduction of the carboxamide functionality at C3 generally leads to an increase in receptor affinity, although compound **11** would seem to be an exception to this general

rule. Curiously, in the series of compounds where R_3 is hydrogen, the n-pentyl amide (**15**) also stands out as exceptional, being the only compound made where an increase in affinity over that observed for the parent compound **17** could be determined. One interpretation of these data may be that the R_1 and R_3 groups compete for a common lipophilic pocket in the receptor. A range of carboxamide substituents were examined; primary, secondary and cyclic amides all showed good to excellent ET_A affinity.

Representative compounds from table 1 were tested *in vivo* after oral (conscious rat) dosing; potency was assessed against the pressor response induced by big ET-1 in Alderley Park rats. A partial dose-response curve to big ET-1 (range 0.1-4.0 nmol kg^{-1} i.v.), sufficient to increase mean arterial pressure $\geq$ 30 mmHg, was obtained prior to, then at various times after, administration of compound in 10% DMSO. Big ET-1 curves were obtained 1h after oral dosing, to conscious rats, in routine screening. Data from representative compounds are shown in table 2 where activity is quoted as the mean dose-ratio (MDR) obtained 1h after oral administration of compound.

Table 2 - Oral Activity of compounds 8 and 10

Compound	R_1	R_2	R_3	$mgkg^{-1}$	MDR (1h)
8	$-CH_3$	H	*i*-Bu	3	2.7
10	$-CH_2CH_2OCH_3$	H	*i*-Bu	3	2.1

Although these data were encouraging we decided to make analogues using the other amino-pyrazines we had identified in our earlier work with compounds **1-3**.[13] The most interesting compounds found were those bearing a methyl group at the C5 position of the pyrazine. The *in vitro* and *in vivo* activities of five compounds in this series are shown in Table 3. In general the compounds show broadly similar affinities for the ET_A receptor and all are highly selective for this receptor over the ET_B receptor (data not shown). However, the compounds were considerably more active *in vivo* than the 5-bromo pyrazine analogues shown in Table 2.

Table 3 - Activity of compounds 18-22

Compound	R_1	R_2	ET_A pIC_{50}	$mgkg^{-1}$	MDR (1h)
18	$-CH_3$	H	9.3	1	3.2
19	H	H	9.0	1	2.4
20	$-CH_2CH_2OH$	H	9.2	1	4.2
21	$-CH_2CH_2OCH_3$	H	9.3	1	3.2
22	$-CH_3$	$-CH_3$	8.6	1	1.6



The analogue which proved to be of greatest interest was N-methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide (**18**). This compound showed a pIC_{50} of 9.3 in the ET_A receptor binding assay which was similar to the value obtained with the corresponding bromo compound, **8**

(pIC_{50} = 8.9). Activity *in vivo* after oral dosing was assessed as before, with mean dose-ratios (MDR) being obtained 30 min, 2h and 4h after administration of **18**, 2.5 $mgkg^{-1}$ (5 animals), or vehicle (12 animals).

Table 4. Oral activity of Compound 18 dosed at 2.5 $mgkg^{-1}$ in the conscious rat.

	30 min	2 hours	4 hours
Vehicle	1.1 [1.0-1.2]	1.1 [1.1-1.2]	1.0 [1.0-1.2]
18	6.2 [4.4-8.9]***	3.3 [1.6-6.6]*	4.0 [2.6-6.3]***

(*P<0.05, *** P<0.001 vs vehicle, Student's t-test for unpaired data).

Results are expressed as mean dose ratios [95% confidence limits] measured at a pressor response of 30 mmHg.

The results shown in table 4 demonstrate that changing the nature of the heterocycle has given **18** a much better oral profile (MDR of 4.0 at 4h when dosed at 2.5$mgkg^{-1}$ dose) when compared to that of its close analogue **8** (MDR of 2.7 at 1h when dosed at 3 $mgkg^{-1}$). Further studies on these compounds are continuing.

In summary, we have prepared a series of ET_A-selective endothelin antagonists which show improved potency over both the unsubstituted biphenylsulphonamides (**16/17**) and the dansyl sulphonamides **1-3**. N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide (**18**) shows high *in vivo* oral potency and, when dosed at 2.5$mgkg^{-1}$ in the conscious rat, has a duration of action in excess of 4h.

References and Notes

1. a) Yanagisawa, M.; Kurihara, H.; Kimura, H.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Goto, K.; Masaki, T. *Nature* **1988**, *332*, 411-415. b) Wilson, C.; Hargreaves, R. B. *Prog. Med. Chem.* **1994**, *31*, 371-410.
2. Masaki, T.; Yanagisawa, M.; Goto, K *Med. Res. Rev.* **1992**, *4*, 391-421.
3. Takashi, K.; Totsune, K.; Mouri, T. *Nephron* **1994**, *66*, 373-379.
4. Cosentino, F.; Katusic, Z. S. *Stroke* **1994**, *25*, 904-908.
5. Gaid, A.; Yanagisawa, M.; Langleben, D.; Michel, R.; Levy, R.; Shennib, S.; Kimura, S.; Masaki, T.; Duguid, W.; Path, F. R. C.; Stewart, D. J. *N. Engl. J. Med.* **1993**, *328*, 1732-1739.
6. a) Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. *Nature* **1990**, *348*, 730-732. b) Sakurai, T.; Yanagisawa, M.; Takuwu, Y.; Miyazaki, H.; Kimuar, S.; Goto, K.; Masaki, T. *Nature* **1990**, *348*, 732-735.
7. a) Panek, R. L.; Major, T. C.; Hingorani, G. P.; Doherty, A. M.; Taylor, D. G.; Rapundalo, S. T. *Biochem. Biophys. Res. Commun.* **1992**, *183*, 566-571. b) Warner, T. D.; Allcock, G. H.; Corder, R.; Vane, J. R. *Br. J. Pharmacol.* **1993**, *110*, 777-782.
8. Ohlstein, E. H.; Arleth, A.; Bryan, H.; Elliott, J. D.; Sung, C. P. *Eur J. Pharmacol.* **1992**, *225*, 347-350.
9. a) Clozel, M.; Gray, G. A.; Breu, V.; Loffler, B.-M.; Osterwalder, R. *Biochem. Biophys. Res. Commun.* **1992**, *186*, 867-873. b) Moreland, S.; McMullen, D. M.; Delaney, C. L.; Lee, V. G.; Hunt, J. *Biochem. Biophys. Res. Commun.* **1992**, *184*, 100-106.
10. Stein, P. D.; Hunt, J. T.; Floyd, D. M.; Moreland, S.; Dickinson, K. E. J.; Mitchell, C.; Liu, E. C.-K.; Webb, M. L.; Murugesan, N.; Dickey, J.; McMullen, D.; Zhang, R.; Lee, V. G.; Serafino, R.; Delaney, C.; Schaeffer, T. R.; Kozlowski, M. *J. Med. Chem.* **1994**, *37*, 329-331.
11. Clozel, M.; Breu, V.; Burri, K.; Cassal, J.-M.; Fischli, W.; Gray, G. A.; Hirth, G.; Loffler, B. M.; Muller, M.; Neidhart, W.; Ramuz, H. *Nature* **1993**, *365*, 759-761.
12. Roux, S. P.; Clozel, M.; Sprecher, U.; Gray, G.; Clozel, J. P. *Circulation* **1993**, *88*, I-170.
13. Bradbury, R.H.; Bath, C.; Butlin, R.J.; Dennis, M.; Heys, C.; Hunt, S.J.; James, R.; Mortlock, A.A.; Sumner, N.F.; Tang, E.K.; Telford, B.; Whiting, E.; Wilson, C. *J. Med. Chem.* **1997**, *40*, 997-1004.
14. a) Murugesan, N.; Hunt, J.T.; Eur. Pat. EP 0 569 193, 1993. b) Chan, M.F.; Raju, B.; Kois, A.; Castillo, R.S.; Verner, E.J.;Wu, C.; Hwang, E.; Okun, I.; Stavros, F.; Balaji, V.N. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2393-2399.
15. Whiting, E.; Bath, C.; Tang, E.; Wilson, C. *Br. J. Pharmacol.* **1995**, *114*, 194P.

(*Received in Belgium* 6 *February* 1997; *accepted* 25 *April* 1997)